ACT Brief: Data Quality as Foundational to Trial Modernization, CRAs Evolving to Strategic Site Partners, and 2026 Emerging Pharma Leaders Announced

This is the Applied Clinical Trials Brief—your fast track to the latest insights shaping clinical operations and drug development.

• In a new FAQ, we addressed data quality across the clinical trial lifecycle, framing it as a layered challenge manifesting differently at every stage from point-of-care sample collection to real-world data curation and wearable device integration. Data quality remains the ceiling on artificial intelligence, real-time oversight, and real-world evidence deployments, yet organizations still lack standardized solutions across trial phases.
• In a new contributed article, Chi-Hui Tang, senior strategic consultant at CluePoints, described how clinical research associates are evolving from compliance-focused manual monitors to data-enabled strategic site partners capable of using analytics to prioritize high-impact activities. Organizations need analytics training, clear operating models, and active change management to make the shift from activity-based monitoring to risk-proportionate oversight.
• Pharmaceutical Executive announced the 2026 Emerging Pharma Leader Awards, recognizing five rising leaders across R&D, operations, and innovation spanning Syndax Pharmaceuticals, Corsera Health, Regeneron, EVERSANA, and Inizio Engage. The honorees were selected for vision and drive in areas including artificial intelligence, scientific marketing, and company building.

That's all for today's ACT Brief. Join us next week for more updates shaping clinical operations and drug development. Thanks for listening.